The Global Trade Research Initiative (GTRI) has cautioned that the proposed steep US tariffs on generic medicines could have a significant impact on India's largest pharmaceutical export market, although the effect is expected to vary across product categories.
According to GTRI, Indian generic medicines are typically priced seven to ten times lower than their branded alternatives. It said as a result, even if a 100 per cent tariff is imposed, many Indian generics are likely to remain cheaper than branded medicines. Consequently, a substantial portion of the additional cost is expected to be absorbed by US healthcare providers, insurers and patients, rather than immediately eliminating Indian exports. It added that the greatest pressure is expected to fall on higher-value generic formulations and branded generics, where manufacturing in the United States could become commercially viable.
GTRI founder Ajay Srivastava said the proposed tariffs could significantly affect India's largest pharmaceutical export market. He also urged India to reduce its reliance on the US by expanding pharmaceutical exports to Europe, Latin America, Africa and Asia.
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: